<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262078</url>
  </required_header>
  <id_info>
    <org_study_id>14-005091</org_study_id>
    <secondary_id>R01HL128526</secondary_id>
    <secondary_id>U10HL110262</secondary_id>
    <nct_id>NCT02262078</nct_id>
  </id_info>
  <brief_title>Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Acute Effects of Inhaled Sodium Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aires Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that
      has no proven effective treatment. This study will assess the effects of nebulized inhaled
      nitrite administration on resting and exercise hemodynamics in patients with HFpEF referred
      to the catheterization lab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients referred to the cardiac catheterization laboratory for invasive exercise stress
      testing will be prospectively recruited. Standard right heart catheterization using high
      fidelity micromanometers (Millar Instruments) will be performed at rest and during supine
      exercise with simultaneous expired gas analysis (Medgraphics) as is the investigator's
      current practice. The protocol is restâ€”passive leg elevation--20 Watts exercise x 5 minutes,
      and then graded workload increases in 10Watt increments (3 minute stages) to exhaustion.
      Hemodynamic, arterial and mixed venous blood gas and expired gas data are acquired at rest,
      during each exercise stage and at peak exercise. Venous blood samples will be obtained at
      rest and at peak exercise. Perceived symptoms of dyspnea and fatigue will be quantified using
      the Borg dyspnea and effort scores at each stage of exercise.

      After the initial exercise study and hemodynamics have returned to baseline, previously
      prepared study drug (normal saline placebo or Sodium Nitrite Inhalation Solution (AIR001)
      90mg placed into the medication chamber) will be nebulized utilizing the Aerogen
      Solo-Idehaler over 10-15 minutes. After a 15 minute observation period post completion of
      nebulization, resting hemodynamic and expired gas data will be acquired exactly as in the
      initial run. Subjects will then repeat the leg elevation-20 Watt x 5 minutes exercise phase.
      Blood samples will be again obtained at rest and with exercise. Subjects will repeat exercise
      only at the 20 Watt stage, rather repeating the entire study. This is done to increase the
      feasibility and shorten the time of the case. The investigators have previously observed that
      the vast majority (&gt;85%) of the elevation in cardiac filling pressures and reduction in
      venous oxygen content in people with HFpEF occurs at the low 20 Watt workload, so repeating
      exercise hemodynamic assessment at this load should be sufficient to detect any clinically
      meaningful treatment effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulmonary Capillary Wedge Pressure During Exercise</measure>
    <time_frame>Baseline, after study drug dosing, approximately 4 minutes after starting exercise</time_frame>
    <description>Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured in millimeters of mercury (mmHg)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo (Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite Inhalation Solution</intervention_name>
    <description>90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.</description>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <other_name>AIR001, NaNO2, Sodium Nitrite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline will be administered (by inhalation) to participants prior to exercise.</description>
    <arm_group_label>Placebo (Saline)</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart Failure with preserved Ejection Fraction (HFpEF) is defined by clinical symptoms
             of dyspnea and fatigue

          -  Normal left ventricular ejection fraction (&gt;/=50%)

          -  And elevated Left Ventricular (LV) filling pressure at cardiac catheterization
             (defined as resting Pulmonary Capillary Wedge Pressure (PCWP)&gt;15 mmHg and/or PCWP
             &gt;/=25 mmHg during exercise).

        Exclusion Criteria:

          -  Systolic Blood Pressure &lt;120 mmHg (during catheterization)

          -  Prior nitrate therapy (within previous 2 weeks)

          -  Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency

          -  Other &quot;non-HFpEF&quot; specific causes of heart failure such as significant valvular
             disease (&gt;moderate left-sided regurgitation, &gt;mild stenosis)

          -  Severe pulmonary disease

          -  Unstable coronary disease or coronary spasm

          -  Primary renal or hepatic disease (end stage renal failure/on dialysis or clinical
             diagnosis of hepatitis or hepatic cirrhosis)

          -  Constrictive pericarditis, or infiltrative, restrictive, or hypertrophic
             cardiomyopathies

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Borlaug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Borlaug BA, Melenovsky V, Koepp KE. Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circ Res. 2016 Sep 16;119(7):880-6. doi: 10.1161/CIRCRESAHA.116.309184. Epub 2016 Jul 25.</citation>
    <PMID>27458234</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Preserved Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were referred to the Rochester, Minnesota Mayo Clinic cardiac catheterization laboratory for invasive hemodynamic exercise stress testing between December 2014 and December 2015.</recruitment_details>
      <pre_assignment_details>Of 70 patients screened, 32 were excluded based upon entry criteria and 12 were excluded based on hemodynamic criteria for Heart Failure with preserved Ejection Fraction (HFpEF) (n=10) or because arterial pressures were too low (n=2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Saline)</title>
          <description>Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
Placebo: Normal saline will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
        <group group_id="P2">
          <title>Sodium Nitrite</title>
          <description>Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
Sodium Nitrite Inhalation Solution: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Saline)</title>
          <description>Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
Placebo: Normal saline will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
        <group group_id="B2">
          <title>Sodium Nitrite</title>
          <description>Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
Sodium Nitrite Inhalation Solution: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="10"/>
                    <measurement group_id="B2" value="67" spread="9"/>
                    <measurement group_id="B3" value="70" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulmonary Capillary Wedge Pressure During Exercise</title>
        <description>Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured in millimeters of mercury (mmHg)</description>
        <time_frame>Baseline, after study drug dosing, approximately 4 minutes after starting exercise</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Saline)</title>
            <description>Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
Placebo: Normal saline will be administered (by inhalation) to participants prior to exercise.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite</title>
            <description>Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
Sodium Nitrite Inhalation Solution: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Capillary Wedge Pressure During Exercise</title>
          <description>Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured in millimeters of mercury (mmHg)</description>
          <units>millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2"/>
                    <measurement group_id="O2" value="-4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to X hours following treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Saline)</title>
          <description>Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
Placebo: Normal saline will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
        <group group_id="E2">
          <title>Sodium Nitrite</title>
          <description>Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
Sodium Nitrite Inhalation Solution: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <description>One episode of vasovagal syncope 4 hours after completing study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Taste perversion</sub_title>
                <description>Salty taste following the nebulizer treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patients with symptoms that might independently cause symptoms were excluded, including severe valvular or coronary heart disease and advanced lung, liver or kidney disease. Cannot determine if results would apply to these co-morbidities.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Barry A. Borlaug, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>Borlaug.Barry@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

